PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), based at the Babraham Research Campus, and the Flow Cytometry Facility at the Babraham Institute today announced a collaboration to develop a cell phenotyping assay to detect cell subpopulations in human blood. Once validated, the bespoke assay will be available as a service in the Flow Cytometry Facility. The collaboration then aims to use the assay to investigate the different cell types present in coronary artery samples collected from patients with CAD consenting to participate in PlaqueTec’s ongoing BIOPATTERN trial.
PlaqueTec and the Flow Cytometry Facility were awarded UKRI-BBSRC Campus Collaboration Funding (2022/2023) by the Babraham Research Campus to design and develop an assay for the identification of different cell types present in human blood samples, for use with spectral cytometers. Cells can then be sorted for downstream follow-on analysis, to further characterise cell type.
The collaborative project aims to utilise the assay to perform cell phenotyping analysis on coronary artery samples obtained from patients in the BIOPATTERN trial using PlaqueTec’s unique sampling device, the Liquid Biopsy System. This exploratory analysis could uncover novel biological insights into the cell types accumulating at coronary disease sites, and the resulting data will be integrated with other multiomics and imaging data collected in the BIOPATTERN trial to better inform precision approaches to CAD treatment.
Dr Diane Proudfoot, Chief Scientific Officer, PlaqueTec commented:“We anticipate these studies will help us to better understand CAD on an individual patient level, informing the development of precision medicine approaches to improve the outcome for patients.”